Inhibition of type A GABA receptors by L-type calcium channel blockers.
D015107:4-Butyrolactone / Q000494:pharmacology; D000818:Animals; D001569:Benzodiazepines; D001665:Binding Sites; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D020746:Calcium Channels, L-Type; D002460:Cell Line; D004095:Dihydropyridines / Q000494:pharmacology*; D005442:Flumazenil / Q000494:pharmacology; D018757:GABA Modulators / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists; D006801:Humans; D007031:Hypothalamus / Q000502:physiology; D007668:Kidney / Q000166:cytology; D016297:Mutagenesis, Site-Directed; D009568:Nitrendipine / Q000494:pharmacology*; D010852:Picrotoxin; D017434:Protein Structure, Tertiary; D051381:Rats; D011963:Receptors, GABA-A / Q000737:chemistry* / Q000235:genetics; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics; D012997:Solvents / Q000494:pharmacology; D013045:Species Specificity; D015032:Zinc
D015107:4-Butyrolactone; D001569:Benzodiazepines; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D004095:Dihydropyridines; D005442:Flumazenil; D018757:GABA Modulators; D058787:GABA-A Receptor Antagonists; D009568:Nitrendipine; D010852:Picrotoxin; D011963:Receptors, GABA-A; D011994:Recombinant Proteins; D012997:Solvents; D015032:Zinc; C038806:1,4-dihydropyridine